synucleinopathy
Sign in to saveAlso known as alpha Synucleinopathies, Synucleinopathies, α-Synucleinopathies
Synucleinopathies are neurodegenerative diseases characterised by the abnormal accumulation of aggregates of alpha-synuclein protein in neurons, nerve fibres or glial cells. The synucleinopathies include Parkinson's disease (PD), dementia with Lewy bodies (DLB), and multiple system atrophy (MSA). Other rare disorders, such as various neuroaxonal dystrophies, also have α-synuclein pathologies.
Research
103,067 papers- Biomarkers of conversion to α-synucleinopathy in isolated rapid-eye-movement sleep behaviour disorder.The Lancet. Neurology · 2021
- α-Synucleinopathy phenotypes.Parkinsonism & related disorders · 2014
- Intestinal macrophages modulate synucleinopathy along the gut-brain axis.Nature · 2026
- STING mediates neurodegeneration and neuroinflammation in nigrostriatal α-synucleinopathy.Proceedings of the National Academy of Sciences of the United States of America · 2022
- Synucleinopathy in Amyotrophic Lateral Sclerosis: A Potential Avenue for Antisense Therapeutics?International journal of molecular sciences · 2022
via PubMed
~6 min read
Encyclopedic overview
8 sectionsContents
- Classification
- Signs and symptoms
- Mechanism
- Diagnosis
- Differential diagnosis
- Management
- See also
- References
Synucleinopathies are neurodegenerative diseases characterised by the abnormal accumulation of aggregates of alpha-synuclein protein in neurons, nerve fibres or glial cells. The synucleinopathies include Parkinson's disease (PD), dementia with Lewy bodies (DLB), and multiple system atrophy (MSA). Other rare disorders, such as various neuroaxonal dystrophies, also have α-synuclein pathologies.
== Classification == The synucleinopathies include Parkinson's disease (PD), dementia with Lewy bodies (DLB), and multiple system atrophy (MSA). Other rare disorders, such as various neuroaxonal dystrophies, also have α-synuclein pathologies.
Excerpted from Wikipedia’s “synucleinopathy” article, available under the CC BY-SA 4.0 licence.